Mirae Asset Global Etfs Holdings Ltd. Uro Gen Pharma Ltd. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $47.1 Billion
- Q2 2025
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 20,209 shares of URGN stock, worth $352,444. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,209
Previous 23,320
13.34%
Holding current value
$352,444
Previous $257,000
7.39%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding URGN
# of Institutions
161Shares Held
39.6MCall Options Held
2.06MPut Options Held
717K-
Rtw Investments, LP New York, NY4.54MShares$79.2 Million0.96% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A63.19MShares$55.6 Million0.08% of portfolio
-
Morgan Stanley New York, NY2.48MShares$43.2 Million0.0% of portfolio
-
Jefferies Financial Group Inc. New York, NY2.2MShares$38.4 Million0.27% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$38.3 Million0.0% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $397M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...